ICU Medical Swings to Profit in Q1 2026 with $30.1M Net Income, Improved Margins
ICUI sits 15% above its 52-week low of $107.
Summary
ICU Medical reported strong first-quarter 2026 results, swinging to a GAAP net income of $30.1 million, a significant improvement from a net loss of $(15.5) million in the prior-year quarter. The company also achieved a 39% GAAP gross margin, up from 35% year-over-year, and saw non-GAAP organic revenue growth of 1% despite a divestiture. These results demonstrate continued operational improvement and profitability following a return to profit in fiscal year 2025, as noted in the recent 10-K. Traders will likely view the positive shift in net income and margin expansion favorably, indicating effective management post-divestiture. Investors should monitor future organic growth trends and the impact of any ongoing regulatory challenges.
At the time of this announcement, ICUI was trading at $123.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $107.00 to $160.29. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.